Latest Ratios: P/E Ratio 74.9x · EV/EBITDA 33.0x · ROE 0.7%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $5.3B | $2.8B | $2.8B | $2.9B | $1.8B | $3.1B | — | — |
| Enterprise Value | $5.3B | $2.7B | $3.1B | $3.3B | $2.1B | $3.1B | — | — |
| P/E Ratio → | 74.92 | 352.00 | — | — | — | — | — | — |
| P/S Ratio | 3.18 | 1.93 | 2.23 | 2.73 | 2.04 | 4.67 | — | — |
| P/B Ratio | 3.54 | 1.81 | 1.93 | 2.01 | 1.16 | 2.02 | — | — |
| P/FCF | 24.79 | 25.03 | 32.61 | — | — | — | — | — |
| P/OCF | 36.54 | 18.84 | 26.05 | — | 33.25 | 331.00 | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.90 | 2.50 | 3.13 | 2.47 | 4.69 | — | — |
| EV / EBITDA | 33.03 | 34.21 | 79.44 | — | — | — | — | — |
| EV / EBIT | 218.90 | 112.34 | — | — | — | — | — | — |
| EV / FCF | — | 24.53 | 36.47 | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 32.4% | 32.4% | 32.2% | 28.6% | 27.6% | 30.2% | 35.6% | 29.4% |
| Operating Margin | 1.7% | 1.7% | -2.5% | -17.9% | -24.5% | -42.9% | 4.1% | 7.2% |
| Net Profit Margin | 0.7% | 0.7% | -4.6% | -17.6% | -25.1% | -46.0% | -10.1% | 2.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | 0.7% | 0.7% | -4.0% | -12.6% | -14.1% | -24.2% | -9.2% | — |
| ROA | 0.4% | 0.4% | -2.7% | -8.7% | -10.5% | -17.6% | -4.1% | 2.0% |
| ROIC | 1.1% | 1.1% | -1.3% | -7.6% | -9.2% | -14.8% | 1.8% | — |
| ROCE | 1.3% | 1.3% | -1.7% | -9.7% | -11.0% | -17.3% | 1.8% | 6.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.13 | 0.13 | 0.34 | 0.36 | 0.32 | 0.10 | 0.37 | — |
| Debt / EBITDA | 2.46 | 2.46 | 12.33 | — | — | — | 7.88 | 3.72 |
| Net Debt / Equity | — | -0.04 | 0.23 | 0.30 | 0.24 | 0.01 | 0.35 | — |
| Net Debt / EBITDA | -0.69 | -0.69 | 8.40 | — | — | — | 7.47 | 3.55 |
| Debt / FCF | — | -0.50 | 3.86 | — | — | — | — | 27.74 |
| Interest Coverage | 2.06 | 2.06 | -1.17 | -8.74 | -10.68 | -7.56 | -1.01 | 2.46 |
Net cash position: cash ($249M) exceeds total debt ($194M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.65 | 1.65 | 1.37 | 1.11 | 1.33 | 2.28 | 1.00 | 0.50 |
| Quick Ratio | 1.65 | 1.65 | 1.37 | 1.11 | 1.33 | 1.96 | 1.00 | 0.50 |
| Cash Ratio | 0.99 | 0.99 | 0.68 | 0.39 | 0.62 | 1.27 | 0.25 | 0.06 |
| Asset Turnover | — | 0.65 | 0.59 | 0.50 | 0.40 | 0.35 | 0.24 | 0.76 |
| Inventory Turnover | — | — | — | — | — | 12.24 | — | — |
| Days Sales Outstanding | — | 24.53 | 38.52 | 43.44 | 43.10 | 54.30 | 42.29 | 32.86 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 1.3% | 0.3% | — | — | — | — | — | — |
| FCF Yield | 4.0% | 4.0% | 3.1% | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | — | — |
| Shares Outstanding | — | $391M | $379M | $367M | $355M | $328M | $374M | $374M |
Includes 30+ ratios · 7 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying LFST stock.
LifeStance Health Group, Inc.'s current P/E ratio is 74.9x. This places it at the 50th percentile of its historical range.
LifeStance Health Group, Inc.'s current EV/EBITDA is 33.0x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 56.8x.
LifeStance Health Group, Inc.'s return on equity (ROE) is 0.7%. The historical average is -10.6%.
Based on historical data, LifeStance Health Group, Inc. is trading at a P/E of 74.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
LifeStance Health Group, Inc. has 32.4% gross margin and 1.7% operating margin.
LifeStance Health Group, Inc.'s Debt/EBITDA ratio is 2.5x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.
Key Metrics
Top Statement Risk
Clinician wage inflation pressure
Metrics are mathematically derived from official filings.
Premium Multiples Pricing Future Margin Expansion
Based on reported figures, LFST trades at a trailing P/E of 76.61 and EV/EBITDA of 33.78, multiples that sit far above the 6.45 to 23.24 EV/EBITDA range of its healthcare peers and imply substantial future growth is already priced in.
The market appears to value LFST as a high-growth services platform rather than a traditional outpatient operator, which is consistent with a forward P/E of 86.81 implying earnings expansion well beyond current levels. With trailing operating margins still near 1.8% on a full-year basis, the multiple depends heavily on sustained margin maturation rather than present earnings power. Investors should monitor whether quarterly margin gains persist, since any stall would leave little valuation cushion.
Adjusted Margins Diverge From Reported Earnings
According to reported quarterly figures, LFST's operating margin rose from negative 0.9% in Q2 2025 to 7.0% in Q2 2026, yet its net margin of 5.4% and stock-based compensation near $19.7M suggest a meaningful gap between headline and economic profitability.
The expansion from negative to mid-single-digit operating margins over four quarters indicates genuine operating leverage as SG&A grew far slower than revenue. However, the persistent gap between reported operating margins and the cited Adjusted EBITDA margin of roughly 15% implies that non-cash compensation and other excluded items absorb a large share of operating profit. Operating margin is therefore the more conservative measure of earning power for this business.
Debt Reversal Reverses Deleveraging Trend
As reported in financial statements, LFST's debt-to-equity ratio climbed from 0.14 in Q2 2026 to 0.31 in Q3 2026 after total debt rose from roughly $200.7M to $461.0M, reversing a multi-year deleveraging path.
Coverage metrics have improved sharply, with interest coverage reaching 12.00 in Q3 2026 against near-zero coverage in 2024, which suggests debt service is currently comfortable. The rapid rise in borrowing after a sustained paydown, however, warrants investigation into its purpose, whether acquisitions or working capital needs. Debt-to-EBITDA rising to 9.60 in the latest quarter indicates that leverage relative to earnings has tightened even if absolute interest burden remains manageable.
Returns Recovering From Near-Zero Baseline
Based on reported figures, LFST's ROIC improved from negative 0.6% in Q2 2024 to 1.6% in Q2 and Q3 2026, a recovery that remains well below the 12.3% ROIC reported by Universal Health Services.
The trajectory points to genuine compounding from a very low base, driven primarily by margin recovery rather than capital efficiency gains, since asset turnover has stayed roughly flat near 0.2x. A goodwill-heavy balance sheet of roughly $1.3B in goodwill against $2.2B in total assets means invested capital is substantial relative to current earnings. Returns will need to climb considerably before they justify the capital base and the premium valuation.
Lagging Peers on Returns, Leading on Growth
Based on reported peer figures, LFST's 1.5% ROE and 4.9% net margin compare unfavorably with Ensign Group's 16.6% ROE and Option Care Health's 16.4%, though LFST's recent 26% revenue growth exceeds most of this group.
The gap in returns appears largely structural, reflecting LFST's labor-intensive model and substantial acquisition-related goodwill that dilutes return metrics relative to asset-light peers. Its growth profile is a clear point of differentiation, but the market is paying a valuation premium for that growth rather than for current profitability. Whether the returns gap narrows depends on whether margin expansion proves durable.
Margin Gains May Not Survive Wage Pressure
Based on reported figures, the most commonly misapplied metric here is EV/EBITDA, which appears to flatter LFST's valuation by excluding the stock-based compensation and clinician costs that drive its economic earnings.
Because labor is the dominant cost and stock-based compensation of $19.7M nearly equaled Q2 2026 net income of $23.6M, EBITDA-based multiples may overstate true cash earning power. Operating cash flow and free cash flow after SBC offer a more conservative lens, though quarterly free cash flow margins have been volatile, ranging from 4.9% to 21.7%. Investors should monitor clinician retention and whether margin improvement holds once wage inflation and SBC are treated as real costs.